EGFR and lung cancer: The successful applying of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC) patients who harbored EGFR mutations has dramatically changed the therapeutic approach of lung cancer and led to a more individualized treatment era.